Alamar Biosciences (NASDAQ:ALMR) Stock: Insider Corporate Gp Vi Ltd. Qiming Sells 111,313 Shares

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $29.89, for a total transaction of $3,327,145.57. Following the completion of the transaction, the insider owned 158,967 shares of the company’s stock, valued at $4,751,523.63. This trade represents a 41.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Monday, November 2nd, Corporate Gp Vi Ltd. Qiming sold 43,930 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.84, for a total value of $1,310,871.20.
• On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.38, for a total value of $4,365,788.28.
• On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The stock was sold at an average price of $32.77, for a total value of $3,304,428.49.
• On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total value of $2,664,822.66.
• On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48.
• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total value of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The shares were sold at an average price of $29.33, for a total value of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total value of $1,988,880.72.

Alamar Biosciences Stock Performance

ALMR traded down $0.40 during midday trading on Thursday, hitting $26.99. The stock had a trading volume of 1,238,729 shares, compared to its average volume of 437,669. The stock has a market capitalization of $1.87 billion and a P/E ratio of -13.77. The company’s fifty day moving average is $30.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85. Alamar Biosciences, Inc. has a 1 year low of $18.84 and a 1 year high of $39.61.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The business had revenue of $33.55 million for the quarter. On average, equities research analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Key Alamar Biosciences News

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68% year over year, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. The company also raised its 2026 revenue outlook to $121 million–$123 million, supporting its growth outlook. Alamar Q3 revenue and guidance
• Positive Sentiment: Alamar is partnering with GSK on a large-scale proteomics study. The collaboration could raise the profile of its NULISA platform, though the announcement did not disclose financial terms. Alamar and GSK proteomics study
• Positive Sentiment: Analysts raised price targets: TD Cowen lifted its target to $36 and BofA Securities raised its target to $35. TD Cowen maintained a Buy rating. TD Cowen rating information BofA price target update
• Neutral Sentiment: The company plans to participate in upcoming investor conferences, providing opportunities to discuss its business and outlook, but no new financial guidance was reported in the announcement. Investor conference announcement
• Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming sold shares in a series of transactions, including 187,636 shares on October 30 and November 2. The sales may pressure sentiment, although the reason for them was not disclosed. Major shareholder sales

Hedge Funds Weigh In On Alamar Biosciences

A number of large investors have recently bought and sold shares of the stock. Sumitomo Mitsui Trust Group Inc. lifted its position in Alamar Biosciences by 18.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after purchasing an additional 10,461 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alamar Biosciences during the third quarter valued at approximately $196,000. State Street Corp bought a new position in shares of Alamar Biosciences in the second quarter worth approximately $3,930,000. Squarepoint Ops LLC bought a new position in shares of Alamar Biosciences in the second quarter worth approximately $283,000. Finally, Braidwell LP bought a new position in shares of Alamar Biosciences in the second quarter worth approximately $29,365,000.

Analyst Ratings Changes

ALMR has been the topic of several recent research reports. Weiss Ratings lowered shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 23rd. TD Cowen boosted their price target on shares of Alamar Biosciences from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday. Stifel Nicolaus upped their price target on shares of Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. raised their price objective on Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alamar Biosciences currently has a consensus rating of “Hold” and an average price target of $33.00.

About Alamar Biosciences

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.